Evaluation of Bone Marrow Morphology is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients
Findings from a recent study add credence to recent World Health Organization (WHO) criteria stressing the importance of the marrow biopsy at diagnosis. Whereas it may be argued that a baseline bone marrow biopsy is not a necessary diagnostic procedure for patients with a significantly increased red cell count and a demonstrable JAK2V617F allele burden, a biopsy establishes initial degree of cellularity and fibrosis that should be used for clinical decisions during the course of the illness.
Haematologica
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology